Skip to main content
Journal cover image

Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis.

Publication ,  Journal Article
Rowell, J; Thompson, AJ; Guyton, JR; Lao, XQ; McHutchison, JG; McCarthy, JJ; Patel, K
Published in: Hepatol Int
April 2012

BACKGROUND: The hepatitis C virus (HCV) is known to disrupt lipid metabolism, making serum lipoprotein levels good candidates to explore as markers of HCV disease progression. Assessment of the major apolipoproteins (Apo) and their relationship to hepatic fibrosis remain largely unexplored. METHODS: We compared the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and Apo A-I, -B, -C-III, and -E between patients with cleared versus active infection (n = 83), and between those chronically infected patients (n = 216) with advanced versus mild-moderate hepatic fibrosis (METAVIR stage F3-4 vs. F0-2) using multiple logistic regression. RESULTS: Apo C-III levels were 25% higher in subjects with cleared infection versus those with active infection (p = 0.009). Low levels of Apo C-III (p = 1.3 × 10(-5)), Apo A-I (p = 2.9 × 10(-5)), total cholesterol (p = 5.0 × 10(-4)), LDL-C (p = 0.005), and HDL-C (p = 2.0 × 10(-4)) were associated with advanced fibrosis in univariate analyses. Multivariable analysis revealed Apo C-III as the most significant factor associated with advanced fibrosis (p = 0.0004), followed by age (p = 0.013) and Apo A-I (p = 0.022). Inclusion of both Apo C-III and Apo A-I in a model to predict advanced fibrosis improved the area under the receiver operator curve only modestly. CONCLUSIONS: Relative to other lipoproteins, low serum Apo C-III levels are the most strongly associated with chronic versus cleared infection and decline with increasing severity of hepatic fibrosis. Apo C-III deserves further attention as a possible marker of HCV disease progression.

Duke Scholars

Published In

Hepatol Int

DOI

ISSN

1936-0533

Publication Date

April 2012

Volume

6

Issue

2

Start / End Page

475 / 481

Location

United States

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rowell, J., Thompson, A. J., Guyton, J. R., Lao, X. Q., McHutchison, J. G., McCarthy, J. J., & Patel, K. (2012). Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int, 6(2), 475–481. https://doi.org/10.1007/s12072-011-9291-x
Rowell, J., A. J. Thompson, J. R. Guyton, X. Q. Lao, J. G. McHutchison, J. J. McCarthy, and K. Patel. “Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis.Hepatol Int 6, no. 2 (April 2012): 475–81. https://doi.org/10.1007/s12072-011-9291-x.
Rowell J, Thompson AJ, Guyton JR, Lao XQ, McHutchison JG, McCarthy JJ, et al. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int. 2012 Apr;6(2):475–81.
Rowell, J., et al. “Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis.Hepatol Int, vol. 6, no. 2, Apr. 2012, pp. 475–81. Pubmed, doi:10.1007/s12072-011-9291-x.
Rowell J, Thompson AJ, Guyton JR, Lao XQ, McHutchison JG, McCarthy JJ, Patel K. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int. 2012 Apr;6(2):475–481.
Journal cover image

Published In

Hepatol Int

DOI

ISSN

1936-0533

Publication Date

April 2012

Volume

6

Issue

2

Start / End Page

475 / 481

Location

United States

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences